Document Detail

Outcomes in women receiving low-molecular-weight heparin during pregnancy.
MedLine Citation:
PMID:  22964770     Owner:  NLM     Status:  MEDLINE    
To assess the rate and type of maternal and infant complications among pregnant women receiving low-molecular-weight heparin (LMWH). Retrospective study of pregnant women on LMWH referred to two university hematology clinics from January 2001 to December 2010. We recorded the number of pregnancies, indication, dose and dose adjustments for LMWH, pregnancy outcomes (live births, maternal and infant complications) and side effects of LMWH. There were 89 pregnancies in 76 women. The most common indication for LMWH was a history of adverse outcome of pregnancy associated with thrombophilia. LMWH was adjusted in 75 and 45% of pregnancies in women on therapeutic and prophylactic doses, respectively. Live birth rate was 97%. There were 25 maternal and 11 infant complications. Side effects were minimal and included decreased bone mineral density and bleeding. LMWH use among pregnant women is associated with successful pregnancy outcomes. Although side effects were minimal, maternal and infant complications occurred in 28 and 12% of cases, respectively.
Maria T De Sancho; Sana Khalid; Paul J Christos
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis     Volume:  23     ISSN:  1473-5733     ISO Abbreviation:  Blood Coagul. Fibrinolysis     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-08     Completed Date:  2013-04-16     Revised Date:  2013-04-18    
Medline Journal Info:
Nlm Unique ID:  9102551     Medline TA:  Blood Coagul Fibrinolysis     Country:  England    
Other Details:
Languages:  eng     Pagination:  751-5     Citation Subset:  IM    
Division of Hematology-Oncology, Department of Medicine, New York Presbyterian Hospital of Weill Cornell Medical College, New York, New York 10021, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticoagulants / therapeutic use*
Heparin, Low-Molecular-Weight / therapeutic use*
Infant, Newborn
Live Birth*
Middle Aged
Pregnancy Complications, Cardiovascular / blood*,  physiopathology
Risk Factors
Thromboembolism / blood,  drug therapy*
Thrombophilia / blood,  drug therapy*
Grant Support
Reg. No./Substance:
0/Anticoagulants; 0/Heparin, Low-Molecular-Weight

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Freezing does not decrease carbon monoxide-mediated hypercoagulation and hypofibrinolysis in human p...
Next Document:  Novel microfluidic platform for automated lab-on-chip testing of hypercoagulability panel.